Kymera Therapeutics (KYMR) News Today $30.13 -1.31 (-4.17%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$30.10 -0.02 (-0.08%) As of 05/21/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KYMR Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period D. E. Shaw & Co. Inc. Lowers Stock Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR)D. E. Shaw & Co. Inc. trimmed its position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 56.1% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 82,578 shares of the company's stock after selling 105,May 21 at 4:03 AM | marketbeat.comKymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the American Thoracic Society International ConferenceMay 19 at 12:15 PM | globenewswire.comJanus Henderson Group PLC Grows Stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR)Janus Henderson Group PLC increased its stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 2,397.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 377,384 shares of the comMay 19 at 4:34 AM | marketbeat.comNorthern Trust Corp Has $17.61 Million Stock Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR)Northern Trust Corp increased its holdings in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 14.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 437,833 shares of the company's stock aMay 17, 2025 | marketbeat.comHC Wainwright Issues Optimistic Estimate for KYMR EarningsMay 17, 2025 | americanbankingnews.comB. Riley Lifts Earnings Estimates for Kymera TherapeuticsKymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) - Stock analysts at B. Riley lifted their Q2 2025 earnings per share estimates for shares of Kymera Therapeutics in a research report issued on Monday, May 12th. B. Riley analyst K. Patel now forecasts that the company will post earnings per sMay 16, 2025 | marketbeat.comComerica Bank Reduces Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR)Comerica Bank trimmed its position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 45.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 20,631 shares of the company's stock after selling 17,442 sharesMay 16, 2025 | marketbeat.comQ2 EPS Estimate for Kymera Therapeutics Boosted by AnalystMay 15, 2025 | americanbankingnews.comThe Analyst Verdict: Kymera Therapeutics In The Eyes Of 4 ExpertsMay 14, 2025 | nasdaq.comKymera Therapeutics: Intriguing Degradation Thesis, But A Bit Powder PuffMay 14, 2025 | seekingalpha.comBank of America Issues Pessimistic Forecast for Kymera Therapeutics (NASDAQ:KYMR) Stock PriceBank of America dropped their price target on shares of Kymera Therapeutics from $47.00 to $44.00 and set a "neutral" rating on the stock in a research report on Monday.May 14, 2025 | marketbeat.comKymera Therapeutics (NASDAQ:KYMR) Receives Buy Rating from GuggenheimGuggenheim reissued a "buy" rating and issued a $52.00 price objective on shares of Kymera Therapeutics in a research report on Monday.May 14, 2025 | marketbeat.comKymera Therapeutics (NASDAQ:KYMR) Earns "Buy" Rating from GuggenheimMay 14, 2025 | americanbankingnews.comBank of America Has Lowered Expectations for Kymera Therapeutics (NASDAQ:KYMR) Stock PriceMay 14, 2025 | americanbankingnews.comKymera Therapeutics (NASDAQ:KYMR) Announces Quarterly Earnings Results, Beats Estimates By $0.10 EPSKymera Therapeutics (NASDAQ:KYMR - Get Free Report) released its earnings results on Friday. The company reported ($0.82) earnings per share for the quarter, beating the consensus estimate of ($0.92) by $0.10. The company had revenue of $22.10 million during the quarter, compared to the consensus estimate of $11.38 million. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. Kymera Therapeutics's revenue was up 114.6% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.69) EPS.May 13, 2025 | marketbeat.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Sold by Frontier Capital Management Co. LLCFrontier Capital Management Co. LLC lowered its stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 61.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 150,172 shares of the company's stock afteMay 12, 2025 | marketbeat.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Q1 2025 Earnings Call TranscriptMay 10, 2025 | msn.comDeerfield Management Company L.P. Series C Makes New Investment in Kymera Therapeutics, Inc. (NASDAQ:KYMR)Deerfield Management Company L.P. Series C bought a new stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 593,000 shares of the company's stock, valued aMay 10, 2025 | marketbeat.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Stake Boosted by Driehaus Capital Management LLCDriehaus Capital Management LLC lifted its position in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 4.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,390,372 shares oMay 10, 2025 | marketbeat.comThe Manufacturers Life Insurance Company Grows Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR)The Manufacturers Life Insurance Company grew its position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 14.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 147,296May 10, 2025 | marketbeat.comDimensional Fund Advisors LP Sells 38,871 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR)Dimensional Fund Advisors LP cut its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 8.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 433,755 shares of the compaMay 10, 2025 | marketbeat.comKymera Therapeutics, Inc. (KYMR) Q1 2025 Earnings Call TranscriptMay 9, 2025 | seekingalpha.comKymera Therapeutics, Inc.: Kymera Therapeutics Announces First Quarter 2025 Financial Results and Provides a Business UpdateMay 9, 2025 | finanznachrichten.deKYMERA THERAPEUTICS Earnings Preview: Recent $KYMR Insider Trading, Hedge Fund Activity, and MoreMay 9, 2025 | nasdaq.comWhat's Next: Kymera Therapeutics's Earnings PreviewMay 9, 2025 | benzinga.comKymera Therapeutics Expands Industry Leading Immunology Pipeline with New First-in-Class, Oral IRF5 Degrader Program with Potential to Address Multiple Immuno-Inflammatory DiseasesMay 9, 2025 | globenewswire.comKymera Therapeutics Announces First Quarter 2025 Financial Results and Provides a Business UpdateMay 9, 2025 | globenewswire.comKymera Therapeutics to Participate in Fireside Chat at the BofA Securities 2025 Health Care ConferenceMay 7, 2025 | globenewswire.comMarshall Wace LLP Reduces Stock Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR)Marshall Wace LLP cut its stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 94.2% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 6,835 shares of the company's stock after selling 110,846 shares during the quMay 7, 2025 | marketbeat.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Given Average Recommendation of "Moderate Buy" by BrokeragesShares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the fifteen analysts that are currently covering the firm, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendationMay 5, 2025 | marketbeat.comBoxer Capital Management LLC Acquires Shares of 425,000 Kymera Therapeutics, Inc. (NASDAQ:KYMR)Boxer Capital Management LLC bought a new position in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 425,000 shares of the company'May 4, 2025 | marketbeat.comSchonfeld Strategic Advisors LLC Buys 36,294 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR)Schonfeld Strategic Advisors LLC raised its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 20.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 215,480 shares of the company's stock after acquiring an additioMay 3, 2025 | marketbeat.comAquatic Capital Management LLC Makes New Investment in Kymera Therapeutics, Inc. (NASDAQ:KYMR)Aquatic Capital Management LLC purchased a new position in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 19,431 shares of tMay 3, 2025 | marketbeat.comInvesco Ltd. Trims Stock Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR)Invesco Ltd. lessened its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 81.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 30,732 shares of the company's stock after sellinMay 3, 2025 | marketbeat.comWells Fargo & Company MN Acquires 7,487 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR)Wells Fargo & Company MN lifted its position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 51.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 21,939 shares of the company's stock after purchasinMay 3, 2025 | marketbeat.comSusquehanna Fundamental Investments LLC Purchases New Shares in Kymera Therapeutics, Inc. (NASDAQ:KYMR)Susquehanna Fundamental Investments LLC acquired a new position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 59,436 shares of the compaMay 2, 2025 | marketbeat.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Acquired by First Trust Advisors LPFirst Trust Advisors LP increased its holdings in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 43.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 176,220 shares of the company's stock after purchasinMay 2, 2025 | marketbeat.comSoros Fund Management LLC Invests $4.84 Million in Kymera Therapeutics, Inc. (NASDAQ:KYMR)Soros Fund Management LLC bought a new stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 120,373 shares of the company's stock, valued aMay 1, 2025 | marketbeat.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Sold by First Light Asset Management LLCFirst Light Asset Management LLC lessened its position in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 5.7% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 383,310 shares of the company's stock after selling 23,038 shares during the period. Kymera ThApril 30, 2025 | marketbeat.comForesite Capital Management VI LLC Takes Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR)Foresite Capital Management VI LLC purchased a new stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 146,332 shares of the company's stock, valued atApril 30, 2025 | marketbeat.comGilder Gagnon Howe & Co. LLC Has $13.13 Million Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR)Gilder Gagnon Howe & Co. LLC increased its stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 12.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 326,349 shares of the company's stock after purchasing an additional 35,009 sharesApril 28, 2025 | marketbeat.comPrice T Rowe Associates Inc. MD Has $276.40 Million Stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR)Price T Rowe Associates Inc. MD grew its position in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 3.4% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 6,870,333 shares of the company's stock after acquiring an additional 224,859 shares during theApril 28, 2025 | marketbeat.comJPMorgan Chase & Co. Lowers Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR)JPMorgan Chase & Co. lowered its holdings in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 73.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 37,065 shares of the company's stockApril 28, 2025 | marketbeat.comKymera Therapeutics (KYMR) Projected to Post Earnings on ThursdayKymera Therapeutics (NASDAQ:KYMR) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 1. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-1-kymera-therapeutics-inc-stock/)April 26, 2025 | marketbeat.comWhy Kymera Therapeutics Stock Crushed it This WeekApril 25, 2025 | fool.comKymera Therapeutics to unveil new oral development candidateApril 25, 2025 | markets.businessinsider.comKymera Therapeutics Advances KT-621 Clinical Trials in Atopic Dermatitis and AsthmaApril 23, 2025 | nasdaq.comKymera Therapeutics (NASDAQ:KYMR) Trading 6.2% Higher - What's Next?Kymera Therapeutics (NASDAQ:KYMR) Trading Up 6.2% - Here's WhyApril 23, 2025 | marketbeat.comAvoro Capital Advisors LLC Boosts Stock Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR)Avoro Capital Advisors LLC increased its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 14.4% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 5,150,000 shares of the company's stock after purchasing an addiApril 23, 2025 | marketbeat.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Sold by Rock Springs Capital Management LPRock Springs Capital Management LP cut its stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 1.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,034,137 shares of the company's stock after selling 15,April 23, 2025 | marketbeat.com Get Kymera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KYMR and its competitors with MarketBeat's FREE daily newsletter. Email Address KYMR Media Mentions By Week KYMR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KYMR News Sentiment▼0.950.65▲Average Medical News Sentiment KYMR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KYMR Articles This Week▼125▲KYMR Articles Average Week Get Kymera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KYMR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ROIV News Today RVMD News Today ELAN News Today BPMC News Today BBIO News Today VRNA News Today TLX News Today TGTX News Today GRFS News Today LNTH News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KYMR) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredWarning: Prepare to Be Shocked by These PayoutsThere's a strategy out there paying up to 70% on tech stocks like Amazon, Tesla, and Microsoft—stocks that don...Investors Alley | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredA new financial chapter Porter Stansberry says what happened last week could become the defining legacy of his financial publishing ca...Porter & Company | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kymera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kymera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy KYMR Stock Free KYMR Stock Alerts